Cardia, Inc. was founded with the mission to innovate and improve the treatment of cardiac defects through minimally invasive solutions. The company's vision is to provide safe, reliable, and effective transcatheter closure devices that eliminate the need for open-heart surgery. Cardia's primary products include the Ultrasept family, designed for the transvenous closure of congenital heart defects such as Atrial Septal Defects (ASD) and Patent Foramen Ovale (PFO). These devices are introduced through standard venous sheaths, allowing patients to undergo procedures with minimal hospital stays.

Notable figures affiliated with Cardia include leading cardiologists and medical device experts who contribute to its research and development efforts. The company has secured investments from prominent venture capital firms specializing in medical technologies. Key achievements include successful clinical trials and regulatory approvals that have positioned Cardia as a trusted name in cardiac care. The overall impact of Cardia's innovations is significant, offering patients less invasive treatment options and improving recovery times, thereby enhancing the quality of life for individuals with congenital heart defects.